Professor Hans Stauss is Programme Chair for the Infection, Immunity and Inflammation Programme at UCLPartners.
In this role he is leading the development of immunotherapy for cancer and chronic infection, improving diagnostics and therapy of inherited diseases, exploiting regenerative medicine technologies to produce the next generation transplants and developing the Institute of Immunity and Transplantation.
Hans is Head of Clinical Immunology at the Royal Free London NHS Foundation Trust, as well as Co-Director of the UCL Division of Infection and Immunity, and his research is focused on T cell biology and cancer immunology.
He has an international reputation as a researcher in cancer immunotherapy. His group has identified protein structures of cancer cells that can be recognised by immune cells and serve as targets for immune-mediated cancer cell killing. More recently, his group developed a strategy to improve immune attack of cancer cells by employing gene therapy, a concept that is now tested in clinical trials.
“UCLPartners has the research and clinical expertise to develop new forms of immunotherapy to treat chronic diseases and prevent the rejection of transplants.”Professor Hans Stauss